Acute bacterial rhinosinusitis is the mucosal inflammation of the nose and paransal sinuses caused by bacteria lasting >10 days for up to 4 weeks or symptoms worsening for 5-7 days and is <12 weeks with complete resolution of symptoms.
It is often preceded by a viral upper respiratory tract infection.
Signs and symptoms are nonspecific and typically difficult to differentiate from viral upper respiratory tract infection.
There is fever with nasal obstruction/congestion or anterior and/or posterior purulent drainage, with or without facial pressure/pain/fullness and reduction/loss of smell. Streptococcus pneumoniae and unencapsulated strains of Haemophilus influenzae cause half of acute rhinosinusitis cases.
Dupilumab significantly improves all disease components of severe, uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP) — a primarily type 2 inflammatory condition — compared with placebo when both are added to standard of care. Furthermore, the treatment benefit extends to even patients with comorbid nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (NSAID-ERD), according to a pooled analysis of the LIBERTY NP SINUS-24 and -52* trials presented at ERS 2019.
A large number of patients who present at outpatient clinics with symptoms of acute respiratory infections (ARIs) during influenza seasons are prescribed antibiotics despite not needing them, a finding that highlights the overuse of antibiotics in ARIs, a recent study showed.
Children who undergo adenoidectomy, tonsillectomy, or both (adenotonsillectomy) within the first 9 years of life may have an elevated long-term risk of respiratory, allergic, or infectious diseases, results from a Denmark-based study show.
There are various ear, nose, and throat (ENT) conditions which present to the GP’s clinic. Dr Jason Hwang, an ENT Consultant from the Department of Otolaryngology at Gleneagles Hospital in Singapore, speaks on how the majority of the conditions can be effectively managed at the primary care level seeing that these can be treated medically without the need for surgical intervention.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Respirology - Malaysia digital copy today!
A shorter regimen comprising a seven-drug cocktail which included high-dose moxifloxacin for 9 months was noninferior to the WHO*-recommended long regimen of 20 months for treating rifampicin-resistant tuberculosis (TB), according to the STREAM** study, providing a feasible and lower-cost treatment option in resource-poor setting.
New drug applications approved by US FDA as of 16 - 31 January 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.